Details of Drug-Drug Interaction
| Drug General Information (ID: DDIE9TRB07) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Elotuzumab | Drug Info | Bacillus calmette-guerin substrain tice live antigen | Drug Info | |||||
| Drug Type | Monoclonal antibody | Vaccine | |||||||
| Therapeutic Class | Antineoplastics | Vaccine | |||||||
| Mechanism of Elotuzumab-Bacillus calmette-guerin substrain tice live antigen Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Elotuzumab | Bacillus calmette-guerin substrain tice live antigen | |||||||
| Mechanism | Immunosuppressive effects | Vaccine or toxoid | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Vaccine/toxoid | ||||||||
| Factor Description | The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations. | ||||||||